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Human motor activity has a robust, intrinsic fractal structure with similar patterns fromminutes to hours.
The fractal activity patterns appear to be physiologically important because the patterns persist under
different environmental conditions but are significantly altered/reduced with aging andAlzheimer’s disease
(AD). Here, we report that dementia patients, known to have disrupted circadian rhythmicity, also have
disrupted fractal activity patterns and that the disruption ismore pronounced in patients withmore amyloid
plaques (a marker of AD severity). Moreover, the degree of fractal activity disruption is strongly associated
with vasopressinergic and neurotensinergic neurons (two major circadian neurotransmitters) in
postmortem suprachiasmatic nucleus (SCN), and can better predict changes of the two neurotransmitters
than traditional circadianmeasures. These findings suggest that the SCN impacts human activity regulation
at multiple time scales and that disrupted fractal activity may serve as a non-invasive biomarker of SCN
neurodegeneration in dementia.
A
ging and dementia are associated with disturbances in sleep and daily activity rhythms1–3 that are themain
reason for the institutionalization of elderly dementia patients. Pathological mechanisms underlying
these behavioral disturbances are not fully understood. One possible mechanism involves neurodegen-
erative changes in the central circadian pacemaker (suprachiasmatic nucleus: SCN) as supported by both human
and animal studies4–7. SCN dysfunction can disrupt circadian rhythms of behavior and physiology and their
synchrony with day-night/light-dark cycles8. Non-invasive and reliable assessment of SCN dysfunction is still a
challenge in human studies. Traditional approaches based on circadian rhythmicity of behavior and core body
temperature can be significantly complicated by many environmental influences such as from housing and light
conditions, nursing home schedules for feeding and sleep, and interactions between patients and caregivers. New
approaches that that are not confounded by these masking effects are needed to define the role of SCN dysfunc-
tion in the progression of dementia.
Fractal fluctuations — similar temporal structures at different time scales — are observed in many neurophy-
siological signals, including motor and brain activity9,10. Such dynamic patterns are robust in healthy physio-
logical systems but are significantly altered/reduced with aging and disease11. Based on experimental and
theoretical physics research, fractal patterns emerge as an integrated behavior on a system level, reflecting net-
works of elaborate feedback processes that interact acrossmultiple control components and across a wide range of
temporal scales12. From lesion studies in rats, we previously found that an intact SCN is necessary for the
maintenance of fractal activity patterns13. In humans we showed fractal activity regulation is reduced with aging
and Alzheimer’s disease (AD)14,15 that are also accompanied by neuroanatomical changes in the SCN4,16. Thus, we
hypothesized that SCN degeneration is responsible for the disrupted fractal activity regulation and that the
disruption increases as AD progresses. To test these hypotheses, we analyzed existing antemortem actigraphy
records (Fig. 1A) of 20 dementia patients (15 AD) and related these results to the number of vasopressinergic and
neurotensinergic neurons in postmortem SCN tissue, and to occipital cortical amyloid plaque burden (a marker
of AD severity) that were all taken from these same patients17. Moreover, we examined whether the use of a
measure of fractal disruption can improve the prediction of the changes in the SCN.
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Results
Altered fractal activity patterns in dementia. To assess fractal
patterns in activity fluctuations, we performed detrended fluctua-
tion analysis (DFA)18 which quantifies fluctuation amplitudes F(n)
across different time scales n. Using the DFA, we previously found
that activity fluctuations of healthy young individuals possess robust
fractal correlations as characterized by a power-law function F(n),
na, with the scaling exponent a, 0.9 (Fig. 1B)15. Here we found that
the fluctuation function of dementia patients generally deviated from
a simple power-law form, displaying different patterns in two time-
scale regions (Fig. 1B). At time scales n,, 2 hours, the fluctuation
function showed a power-law form with the exponent a1 5 1.13 6
0.03 (SE). At time scales n., 2 hours, the fluctuation function also
showed a power-law behavior but the exponent a2 (the exponent a at
time scales., 2 hours) was smaller than a1 (the exponent a at time
scales , , 2 hours) (Fig. 1 B to C). The difference in fractal
correlations between the two regions indicates an overall reduction
of fractal regulation. Thus, we used the difference between the two
exponents (Da 5 a1 2 a2; mean 6 SE: 0.25 6 0.05) to quantify the
degree of disturbed fractal regulation: a larger Da indicates more
disrupted fractal regulation.
Associations between fractal activity disruption and circadian
neurotransmitters. Next, we tested whether the disturbed fractal
activity regulation in these dementia patients reflected SCN
dysfunction. We quantified SCN neurons containing vasopressin
or neurotensin that were obtained from postmortem hypothalamic
tissue samples of these patients17. We found that Da was negatively
correlated with the number of neurons containing the two major
SCN neurotransmitters (vasopressin: p 5 0.0029; neurotensin: p 5
0.014) (Fig. 2A, B; Model 1 in Table 1). Together, the two circadian
neurotransmitters accounted for 72% of variation in Da. These
relationships between disrupted fractal activity and SCN neuro-
transmitters remained after adjusting for age, latency between
behavioral activity recording and time of death (mean 6 SE: 0.57
6 0.13 years), and daily rhythm of neurotransmitter content (see
Methods).
Effect of severity of Alzheimer’s disease. We then tested whether
disturbed fractal activity regulation was specifically related to
neurodegenerative changes in the SCN associated with dementia,
independent of AD severity per se. To estimate AD severity, we
measured amyloid plaque density in the occipital cortex19. After
adjusting for the effect of plaque density, we found an even more
significant association between fractal disruption and vasopressin
cell number in the SCN (Fig. 2C, Model 2 in Table 1). This result
indicates that the association between vasopressin and fractal
disruption is independent of AD severity. However, the association
between neurotensin and fractal activity control was related to AD
severity because this association became not significant (p . 0.3)
after controlling for plaque density and vasopressin. Furthermore,
after accounting for the effect of vasopressin, we also observed a
positive correlation between Da and plaque density (p 5 0.0032)
(Fig. 2D), suggesting that patients with more severe AD had more
disrupted fractal regulation.
Prediction for changes of neurotransmitters in the SCN. We
further examined how the altered fractal activity patterns can help
to predict changes in circadian neurotransmitters and how such a
fractal marker compares tomore traditional markers.We considered
three traditional circadian measures: (1) the circadian amplitude of
core body temperature: 0.32 6 0.03 (SE) uC, range: 0.11 – 0.72uC; (2)
the circadian amplitude of motor activity: 116 6 25, range: 1.7 – 427;
and (3) intraday variability in motor activity: 1.156 0.08, range: 0.42
– 1.82. The regression model with the three circadian measures
accounted for 38% of variation in vasopressin (Model 3a in
Table 1: R2 5 0.38, p 5 0.058, AICc 5 90.8). Adding Da to the
model significantly improved the prediction to 66% (Model 3b in
Table 1: R2 5 0.66, p 5 0.032, AICc 5 75.1). The reduced AICc
indicated a better model fit when Da was added to the model
(adjusting for the number of factors in the model). The effect of
Da on a model in predicting neurotensin was even larger. Without
including Da, the three circadian measures together could account
for only 18% of variation in neurotensin (Model 4a in Table 1). With
Da, 77% of variation in neurotensin could be explained (Model 4b in
Table 1). In both models (for vasopressin and neurotensin,
respectively), Da was the single most significant predicting factor.
In addition, the nadir of cosinor fit of temperature was at 7:55AM
6 0.6 hours (SE) in these dementia patients, delayed for , 5 hours
as compared to the elderly controls (nadir at , 3AM) as previously
reported20–23. However, adding the temperature nadir did not
improve the fits of the models for vasopressin and neurotensin in
these patients because this circadian phase measure was not assoc-
iated with the two neurontransmitters (both p . 0.65).
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Figure 1 | Alterations of fractal correlations in motor activity
fluctuations in dementia patients. (A) 72-hour activity recording of a
representative dementia patient. (B) Detrended fluctuation function F(n)
of the activity signal shown in (a). F(n) displayed different power-law
behavior with different scaling exponent, a1 and a2, at time scales smaller
than and larger than , 2 hours (indicated by dotted dashed line). For
comparison, F(n) of young adults as observed in a previous study13 was also
plotted (dashed black line). (C) Difference between a1 and a2 for all
subjects (except for 5 individuals with no a2 due to many missing data
points in their recordings). The subject # 13 (filled circle) is the patient
whose data are shown in (A) and (B).
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Figure 2 | More disrupted fractal activity correlations in dementia patients with more reduced neurotransmitter in the SCN. (A) Da 5 a1 2 a2 was
negatively correlated with the number of vasopressin-positive SCN neurons after adjusting for the effect of the number of neurotensin-positive SCN
neurons. (B)Dawas correlated with the number of neurotensin-positive SCN neurons after adjusting for the effect of the number of vasopressin-positive
SCN neurons. Results in (A) and (B) were obtained from 13 subjects with dementia (10 with AD) using a regression model in which the two SCN
neurotransmitters (vasopressin and neurotensin) were included as two factors (See Model 1 in Table 1). (C) a1-a2 was correlated with the number of
vasopressin-positive SCN neurons after adjusting for the effect of AD severity as characterized by the plaque density from occipital Bielschowsky stain.
(D) a1-a2 was correlated with the AD severity after adjusted for the effect of the number of vasopressin-positive SCNneurons. Results in (C) and (D) were
obtained from 13 subjects with dementia (9 with AD) using a regressionmodel in which vasopressin neuronal density and plaque density were included as
two factors (see Model 2 in Table 1).
Table 1 | Specification of regression models for prediction of disrupted fractal activity regulation (Models 1 and 2) and SCN neurotrans-
mitters (Models 3 and 4). p1: p values for models; p25p values for independent factors; AICc: corrected Akaike’s information criterion value;
ACBTR: amplitude of core body temperature rhythm, AMAR: amplitude of motor activity rhythm, IV: intraday variability
Response DFtotal DFmodel R2 p1 AICc Fixed Effects t Ratio p2
Model 1 Da 12 2 0.72 0.0018 27.1 vasopressin 23.92 0.0029
neurotensin 22.97 0.014
Model 2 Da 12 2 0.78 0.0005 211.6 vasopressin 25.19 0.0004
plaque density 3.86 0.0032
Model 3a vasopressin 18 3 0.38 0.058 90.8 ACBTR 20.78 0.45
AMAR 21.60 0.13
IV 22.76 0.015
Model 3b vasopressin 13 4 0.66 0.032 75.1 ACBTR 20.78 0.45
AMAR 21.26 0.24
IV 21.9 0.09
Da 22.42 0.039
Model 4a neurotensin 16 3 0.18 0.45 85.3 ACBTR 1.28 0.22
AMAR 0.89 0.39
IV 0.58 0.57
Model 4b neurotensin 11 4 0.77 0.023 63.1 ACBTR 0.40 0.70
AMAR 2.79 0.027
IV 2.96 0.021
Da 23.88 0.0061
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Discussion
Fractal patterns are a robust, intrinsic characteristic of motor activity
regulation in healthy young humans14,15. Similar to disrupted cir-
cadian rhythmicity, disrupted fractal activity patterns in dementia
reflect behavioral disturbances in these patients. The positive asso-
ciation between the fractal disruption and AD severity indicates that
complex behavioral organization deteriorates as AD progresses. The
effect of AD severity on fractal regulation may be partially mediated
through its influence on neurotensin because: (i) senile plaque
formation associated with AD severity is thought to contribute to
neurodegeneration and neurotransmitter changes in the SCN (and
not the other way around); (ii) plaque density was correlated with
neurotensin content (p 5 0.016) (Fig. 3); and (iii) the effect of neu-
rotensin on Da became not significant (p . 0.3) after controlling
plaque density and vasopressin. Moreover, the strong correlation
between the disrupted fractal activity and SCN neurotransmitters
provides evidence that the SCN dysfunction underlies disturbed
fractal regulation in dementia. It is worth noting that fractal activity
patterns reveal a unique aspect of behavioral control at multiple time
scales (i.e., dynamic properties of activity fluctuations from minutes
to hours) that is different from and complementary to circadian
rhythmicty24. Thus, the impact of the SCN dysfunction on fractal
activity patterns also suggests a multiscale regulatory function of the
human SCN.
Based on concepts of modern statistical physics and nonlinear
dynamic theory, fractal activity patterns aremore resilient to external
influences (e.g., scheduled behavior and environmental conditions)
that can significantly impact traditional measures such as mean,
variation and rhythmicity of motor activity14,15,25. For instance,
dementia patients in a nursing homemay have regular daily schedule
of interactions with caregivers. These scheduled events can induce
apparent 24-hour rhythmicity in activity fluctuations even thought
patients themselves may have abolished endogenous circadian con-
trol (Figure 4). In contrast, scheduled events have less impact on
fractal patterns in activity fluctuations. Thus, fractal measures may
better reflect intrinsic alterations in the circadian control network.
Consistently, this study showed that fractal activity patterns are very
sensitive to neuronal changes in the SCN. The single fractal measure
increased the combined predictive power of three traditional cir-
cadian measures by, 1.7 times for vasopressin, and by, 4.2 times
for neurotensin. These results do not refute the value of traditional
circadian measures for the assessment of SCN dysfunction. Indeed
both fractal and circadian measures clearly showed altered beha-
vioral control in dementia and/or AD patients14,15,17
Identifying and monitoring the SCN dysfunction and its assoc-
iated behavioral disturbances are particularly important for demen-
tia care. With an identified target (i.e., neuronal degeneration in the
SCN), more efficient therapies and treatments may be designed to
improve the quality of life of people with the disease. For instance,
light and/or melatonin can be used to restore perturbed circadian
rhythms of physiological functions (e.g., disrupted sleep, daily beha-
vioral cycles, and cognition) that are associated with the SCN dys-
function26,27. Our results suggest that disrupted fractal activity may
server as a non-invasive, sensitive biomarker for SCN deterioration
in dementia. However, without a comprehensive mechanistic under-
standing of fractal regulation and its degradation in dementia, inter-
ventions/treatments targeted at restoring the regulation in dementia
patients are still not feasible at the current stage. Despite the rel-
evance of the SCN to fractal activity patterns as indicated by this
and previous studies4–7, the neurophysiological basis for fractal regu-
lation is still elusive. One possible theory is related to the interactions
between different physiological functions. To achieve an ideal system
performance, maintaining circadian rhythmicity in behavior and
physiology is important but may not be sufficient. An appropriate
orchestration of circadian rhythms in different physiological pro-
cesses (their phase relationship) is demanding and is believed to be
the important functional role of themaster circadian clock28. Can the
involvement of the SCN in fractal regulation reflect the dynamic
process of the SCN-enabled orchestration among many physio-
logical functions? If confirmed, the theory should provide a specific
neurophysiological basis for the widely accepted belief that fractal
patterns in physiology indicates system integrity and flexibility11.
Further studies are warranted to test this hypothesis and to deter-
mine the neural circuitry for fractal regulation.
This is a pilot study with a small sample size. In this study we only
considered two major circadian neurotransmitters in humans, i.e.,
vasopressin and neutotensin. Another important circadian neuro-
transmitter in mammals is vasoactive intestinal peptide (VIP) that
was not assessed in the human study. How the change in VIP affects
fractal activity regulation should be examined in further studies.
Furthermore, large-scale longitudinal studies are needed to deter-
mine the time course of fractal activity disruptions during the pro-
gression of dementia and to test whether fractal disruptions can serve
as a diagnostic marker for the early onset of the disease process.
Methods
Subjects. We utilized existing data from 20 male, dementia patients (62–80 years)
including 15 with Alzheimer’s Disease (AD), 4 with frontotemporal dementia, and 1
with dementia with Lewy bodies who were residing at the E. N. Rogers Memorial
(ENRM) Veterans Administration (VA) Hospital Geriatric Research, Education and
Clinical Center (GRECC) in Bedford,MA.All subjects were admitted with a diagnosis
of possible or probable dementia disease17. Dementia (or AD) was confirmed after
postmortem neuropathological diagnosis (see below). Among the 15 AD patients,
there were three subjects with Braak stage 3–4 and eleven subjects with Braak stage 5–
6 (Braak stage for one subject missing). The Institutional Review Boards of the
McLean and ENRM VA Hospitals approved the protocol and informed consent for
this study. Informed consent was obtained from the subject’s next-of-kin in
accordance with the VA’s human subjects’ research policies on surrogate consent.
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Figure 3 | Association between neurotransmitter content in the SCN and
amyloid plaque density in the occipital cortex. Only neurotensin neuronal
density (not assessed in 1 AD and 1 frontotemporal dementia patients) was
significantly associated with plaque density (R2 5 0.35, p 5 0.016), i.e.,
patients with more plaques had fewer neurotensin-positive SCN neurons.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2229 | DOI: 10.1038/srep02229 4
Study procedure. Details of the procedure were published previously17. Briefly,
following provision of informed consent, physiological recordings were obtained
every 6 months for the duration of the 3-year data collection portion of the study
using a 72 hour data-collection protocol. All subjects were free from significant
intercurrent illness and were taking no antipyretic medication for at least 24 hour
prior to the time of physiological recording. Subjects were studied in their accustomed
environment on the GRECC unit following standard ward routines. No effort was
made to control light, food, nursing care, the patient’s sleep schedule or any other
masking influences during data collection. The age of patients at time of last study was
69.5 6 1.5 (SE) years. Upon death of the subjects, consent was obtained from the
subjects’ next-of-kin for autopsy and subsequent donation of their brains to the
Alzheimer’s Disease Research Center Brain Bank at the ENRMVAHospital. Consent
for this portion of the study was obtained independently without any linkage to the
prior, physiological data collection. At time of death subjects’ mean agewas 70.16 1.4
(SE) years with a mean latency from last physiological recording to death of 0.57 6
0.13 (SE) years (themaximum latency, 2 years). Only 6 subjects survived to undergo
the protocol more than once.
Data acquisition. During each 72-hour data collection protocol, locomotor activity
data were recorded continuously collected by an ambulatory activity monitor (AM-
16, Ambulatory Monitoring Inc., Ardsley, NY) featuring a piezoelectric bender
sensitive to accelerations of 0.01 g. Activity counts were accumulated over 5 minute
epochs and written to memory. Core body temperature was recorded simultaneously
by a rectal thermistor (YSI, series 400, Yellow Springs, OH) that sampled the
temperature data every 6 minutes throughout the 72-hour data-collection period. All
activity and temperature recordings except for one AD patient have been previously
published17 and were used for a secondary analysis in this study.
Neuropathological examination.Brains were coronally sectioned after being fixed in
neutral buffered formalin for. 4 weeks. Then the hypothalamus was dissected from
the brains for the examination of the suprachiasmatic nucleus (SCN). Fourteen
different brain areas were then sampled to determine the diagnosis of Alzheimer’s
disease, dementia with Lewy bodies and other neurodegenerative dementias in
accordance with standardized criteria4,29. To quantify the severity of AD, the amyloid
plaque density was measured in the occipital cortex using Bielschowsky silver stain
(not available in 2 AD patients)19. Neuropathologic diagnoses were confirmed
independently by two board-certified neuropathologists.
SCN immunohistochemistry. Utilizing stereological sampling methods17 in
accordance with the principles described by Weibel30, the degeneration and function
of the SCN were quantified by glia/neuron ratio and by counts of SCN-neurons
containing vasopressin or neurotensin, respectively. Hypothalami were blocked,
embedded in paraffin and serially sectioned at 8 microns in the coronal plane; the
dorsal subdivision of the SCN was identified by examining the Nissl-stain; nuclear
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Figure 4 | Effects of scheduled daily events on assessments of circadian rhythmicity and fractal patterns. (A) Simulated 72-hour activity recording that
possesses fractal correlations but no 24-h rhythm. (B) The same signal as shown in A except for an increased activity level between 9AM and 4PM that was
used to simulate the environmental influence due scheduled daily events. (C) Fourier amplitudes of the signals shown in (A) and (B). (D) Detrended
fluctuation function F(n) of the signals shown in (A) and (B). Daily events led to a significant 24-hour rhythm (C) but barely affected fractal patterns as
revealed by detrended fluctuation analysis (D).
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diameter and cell density were used to localize the centre of the nucleus; sections from
200 microns on either side of the centre of the dorsal SCN were stained sequentially
with Nissl, Bielschowsky silver, Nissl combined with glial fibrillary acidic protein
(GFAP), vasopressin and neurotensin; the area of greatest cell density on each slide
was selected for analysis. For all cell-counting protocols (glia/neuron ratio,
neurotensin and vasopressin) only cells with complete cytoplasmic borders and a
clearly visible nucleus were recorded, and the counts obtained from ten separate
random 0.13 0.1 mm2 fields were averaged. Neurotensin content was not assessed in
2 subjects (1 AD and 1 frontotemporal dementia patients). Glia to neuron ratio was
determined by examination of GFAP/Nissl-stained sections. Cells were identified by
their respective astrocytic or neuronal staining patterns. The neuroanatomical data
except for one AD patient have been previously published17 and were used for a
secondary analysis in this study.
Circadian/daily rhythms. To assess circadian/daily rhythmicity, we quantified the
amplitude of core body temperature (CBT) rhythm, the amplitude of motor activity
rhythm, and intraday variability in motor activity — a measure characterizing
fragmentation of the activity rhythm31. To estimate the amplitudes of CBT and
activity rhythms, we performed cosinor analyses to fit data using a single harmonic
cosine function (24 hours). We calculated the intraday variability by measuring the
hour-to-hour variance in the activity data.
Adjustment for daily rhythm in neurotransmitter content. It has been shown that
vasopressin synthesis of the human SCN exhibits a circadian or diurnal rhythm32.
Due to this rhythmicity, time of death could influence the estimated vasopressin
neuronal density. By pooling data from all subjects, we confirmed a significant 24-
hour rhythm in vasopressin-containing SCN neurons (p 5 0.03)17. Based on the
group averaged rhythm, we adjusted the number of vasopressin-containing SCN
neurons using cosinor analysis. The analysis based on the adjusted measure (i.e.,
residue from cosinor fitting) confirmed but did not significantly improve the
identified relationship between vasopressin neuronal density and fractal regulation.
Given that the postmortem technique only allowed assessment of neurotransmitter
content at a single time point per person, any individual differences in the day/night
rhythm in vasopressin could not be established. Therefore, the adjustment based on
the group average may not reliably account for the effect of time of day on
neurotransmitter content for each individual, especially for these dementia patients
with disrupted circadian/daily rhythms. In addition, the observed 24-hour rhythm of
vasopressin, that was published before17, suggests that the SCNs in some subjects
remained rhythmic to a certain degree. No significant dependence of neurotensin
neuronal density on time of death was observed in these patients.
Fractal analysis. To estimate fractal patterns in the activity fluctuations at different
time scales, we used the detrended fluctuation analysis (DFA)18. Compared with
traditional correlation analyses such as power spectral analysis andHurst analysis, the
DFA can accurately quantify correlations in signals that may be masked by
underlying nonstationarities or trends33. This method quantifies the detrended
fluctuation function, F(n), of activity fluctuations at different time scales n. The DFA
algorithm includes four steps: (i) removing the global mean and integrating the time
series of an activity signal; (ii) dividing the integrated signal into non-overlapping
windows of the same chosen size n; (iii) detrending the integrated signal in each
window using polynomial functions to obtain residuals; and (iv) calculating the root
mean square of residuals in all windows as fluctuation amplitude F(n). The same four
steps were repeated for different time scale n. To eliminate the effect of possible linear
trends in original data, we applied the 2nd order DFA, i.e., the 2nd order of polynomial
functions were used to detrend data34. A power-law form of F(n) indicates self-
similarity (scale-invariance) in the fluctuations, yielding F(n), na. The parameter a,
called the scaling exponent, quantifies the correlation properties in the signal as
follows: if a 5 0.5, there is no correlation in the fluctuations (‘‘white noise’’); if a .
0.5, there are positive correlations, where large activity values are more likely to be
followed by large activity values (and vice versa for small activity values). The
exponent a5 1.0 indicates highest complexity in the systems. Similar a values (close
to 1.0) have been observed in many neurophysiological outputs under normal
conditions, indicating complex feedback interactions9–11. A further increase in a (. 1)
suggests more regular or predicted fluctuations. A special case is a 5 1.5 as observed
in Brownian motion which is the integral of a white noise signal, i.e., increments of
fluctuations are white noise.
In 5 recordings (4 AD and 1 non-AD patients), F(n) could only be obtained at time
scales,, 4 hours due to missing data in those recordings. Thus, the range of time
scales for estimating the scaling exponent at n . 2 hours was too small to obtain
reliable a2 for the 5 subjects.
Statistics. To determine effects of the SCN dysfunction on fractal activity regulation,
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